1908409-18-6
1908409-18-6 structure
- Name: DOTA Zoledronate
- Chemical Name: 2,2',2''-{10-[2-({2-[1-(2-Hydroxy-2,2-diphosphonoethyl)-1H-imidazol-4-yl]ethyl}amino)-2-oxoethyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triyl}triacetic acid
- CAS Number: 1908409-18-6
- Molecular Formula: C23H41N7O14P2
- Molecular Weight: 701.56
- Catalog: Research Areas Cancer
- Create Date: 2022-02-17 22:56:23
- Modify Date: 2025-08-25 12:57:14
-
DOTA Zoledronate is a next-generation agent for bone targeted radionuclide therapy for diagnosing bone metastases[1].
| Name | 2,2',2''-{10-[2-({2-[1-(2-Hydroxy-2,2-diphosphonoethyl)-1H-imidazol-4-yl]ethyl}amino)-2-oxoethyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triyl}triacetic acid |
|---|---|
| Synonyms |
2,2',2''-{10-[2-({2-[1-(2-Hydroxy-2,2-diphosphonoethyl)-1H-imidazol-4-yl]ethyl}amino)-2-oxoethyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triyl}triacetic acid
1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[2-[1-(2-hydroxy-2,2-diphosphonoethyl)-1H-imidazol-4-yl]ethyl]amino]-2-oxoethyl]- |
| Description | DOTA Zoledronate is a next-generation agent for bone targeted radionuclide therapy for diagnosing bone metastases[1]. |
|---|---|
| Related Catalog | |
| In Vitro | DOTA-Zoledronate is a promising agent for the development of other future-oriented radionuclide therapy concepts for personalized nuclear oncology[1]. |
| References |
[1]. The ITM Group Announces In-Licensing of DOTA-Zoledronate Theranostic Agent. |
| Density | 1.7±0.1 g/cm3 |
|---|---|
| Molecular Formula | C23H41N7O14P2 |
| Molecular Weight | 701.56 |
| Exact Mass | 701.218689 |
| LogP | -3.89 |
| Index of Refraction | 1.670 |